A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension

Journal of Clinical Hypertension

Volumn 12, Issue 6, 2010, Pages 414-421

  Zheng, Zhenfeng ^a   Lin, Shan ^a   Shi, Huilan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; TELMISARTAN; VALSARTAN;

ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FOLLOW UP; HEADACHE; HUMAN; INFECTION; META ANALYSIS; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CONFIDENCE INTERVALS; DIASTOLE; DIURETICS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; RISK; SYSTOLE; TETRAZOLES; VALINE;

EID: 77954170155     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00287.x     Document Type: Article

References (14)

1. Rahmouni K, Correia ML, Haynes WG. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005, 45:9-14.
2. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press Suppl 2001, 10:6-10.
3. Kakuta H, Sudoh K, Sasmata M. Telmisartan has the strongest binding affinity to angiotensin II type I receptor: comparison with other angiotensin II type I receptor blockers. Int J Clin Pharmacol Res 2005, 25:41-46.
4. Wienen W, Entzeroth M, van Meel JCA. A review on telmisartan: a novel, long-acting angiotensin II receptor antagonist. Cardiovasc Drug Rev. 2002, 18:127-156.
5. Lasko BH, Laplante A, Hebert D. Canadian valsartan study in patients with mild-to-moderate hypertension. Blood Press Monit. 2001, 6:91-99.
6. McClennan KJ, Markham A. Telmisartan. Drugs. 1998, 56:1039-1044.
7. Bakris G. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2002, 4(4 suppl 1):26-31.
8. Calvo C, Hermida RC, Ayala DE. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004, 22:837-846.
9. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004, 17:347-353.
10. Galle J, Schwedhelm E, Pinnetti S. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008, 23:3174-3183.
11. Sharma AM, Davidson J, Koval S. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cariovasc Diabetol. 2007, 6:28.
12. White WB, Murwin D, Chrysant SG. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press Monit. 2008, 13:21-27.
13. Lewington S, Clarke R, Qizilbash N. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 60 prospective studies. Lancet 2002, 14:1903-1913.
14. Cook NR, Cohen J, Hebert PR. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995, 155:701-709.